

particular aspect of the allegation that Defendant engages in the pharmaceutical manufacturing business in its own name, and is not intended as a means to subject the witness to a wide-ranging examination on the substance of the Second Amended Complaint as a whole.

2. The factual basis of Defendant's admissions and contentions in other legal actions since 1992 to which it has been a party which are contrary to its current position in this case that it has not made, marketed or sold any of the Deposition Drugs (listed at Exhibit A). This topic will address (by way of example, and not limitation) the admissions made in Defendant's Answer to the Amended Master Consolidated Class Action Complaint, Modified Per the Court's Instruction at the November 21, 2003 Hearing, filed in AWP MDL No. 1456 on April 9, 2004, at paragraph 4, that Defendant "manufactures certain drugs" and "reports pricing information for their medicines to pharmaceutical pricing industry pricing publications."
3. The nature and extent of Defendant's participation in the discovery in this case, including, but not limited to the actions taken by Defendant, or in its behalf, to respond to the interrogatories and requests for production propounded by Plaintiff to the date of this notice, and the organization and general subject matters of the documents it has produced in this lawsuit to date. This topic is designed to obtain an understanding of the nature and sources of the hundreds of thousands of pages of documents and data produced in this lawsuit to date, to the extent that they have been produced by Defendant, and is not calculated to subject the witness to a detailed examination on the particular substance of the documents or data themselves, except as they pertain directly to other topics in this notice.

4. The corporate history and organizational structure of Defendant and any predecessor entities.
5. Direct communications between Defendant (or Defendant's counsel or representatives) and the State of Wisconsin Attorney General's Office and/or the State of Wisconsin Medicaid agency.
6. The formal corporate relationship between Schering-Plough Corp. and each of its subsidiaries Schering Corp. and Warrick Pharmaceuticals Corporation.
7. The day-to-day reporting and approval relationships between each of the companies listed in paragraph 6.
8. The Board of Directors of each of the companies listed in paragraph 6.
9. The types of documents regularly exchanged between each of these companies and their employees.
10. The existence of documents reflecting or evidencing any policies or practices regarding Schering-Plough Corp.'s (or its employees') approval of, or contribution to, pricing actions (including the setting of prices of whatsoever kind or the publication thereof) taken by Schering-Plough Corp.'s subsidiaries Schering Corp. or Warrick Pharmaceuticals Corporation.
11. A description of which company pays the salary and bonuses of employees of the companies listed in paragraph 6.
12. Identification of the existence, location and format of all hard copy and electronic documents, data, and information relating to the subjects identified in paragraphs 1-11, above.

The designated deponents shall bring with them evidence or information sufficient to identify each lawsuit or formal administrative agency action commenced since 1992 within the United States in which Defendant contended or admitted, or in which a formal judicial or administrative finding was made, that it either manufactured, marketed, or sold a Deposition Drug.

Dated this 3rd day of March, 2008.



One of Plaintiff's Attorneys

MICHAEL WINGET-HERNANDEZ
State Bar #21769650 (Texas)
Admitted pro hac vice

Winget-Hernandez, LLC
101 S. College St.
Dripping Springs, TX

Exhibit A – Deposition Drugs

CLARI NEX

00085-1264-01
00085-1264-02

CLARI TIN

00085-0458-01
00085-0458-03
00085-0458-04
00085-0458-05
00085-0458-06
00085-0612-02
00085-0635-01
00085-0635-04
00085-0635-05
00085-1128-02
00085-1223-01
11523-7163-01

CLARI TIN-D

00085-0640-01
00085-1233-01
00085-1233-02
11523-7161-02
11523-7162-01

DI PROLENE

00085-0517-01
00085-0517-02
00085-0517-04
00085-0575-02
00085-0575-03
00085-0575-05
00085-0634-01
00085-0634-02
00085-0634-03
00085-0962-01
00085-0962-02

ELOCON

00085-0370-01
00085-0370-02
00085-0567-01
00085-0567-02
00085-0854-01
00085-0854-02

EULEXI N

00085-0525-03
00085-0525-04
00085-0525-06

I NTRON

00085-0120-02
00085-0285-02
00085-0539-01
00085-0571-02
00085-0647-03
00085-0647-04
00085-0647-05
00085-0923-01
00085-0953-01
00085-1110-01

00085-1133-01
00085-1168-01
00085-1179-02
00085-1184-01
00085-1184-02
00085-1191-02
00085-1235-01
00085-1242-01
00085-1254-01

LOTRI SONE

00085-0809-01
00085-0924-01
00085-0924-02

NASONEX

00085-1197-01

PEG- I NTRON

00085-1279-01
00085-1291-01
00085-1297-01
00085-1304-01
00085-1316-01
00085-1323-01
00085-1368-01
00085-1370-01

PROVENTI L

00085-0208-02
00085-0209-01
00085-0431-02
00085-0431-03
00085-0431-04
00085-0614-02
00085-0614-03
00085-1132-01

REBETOL

00085-1194-03
00085-1327-04
00085-1351-05
00085-1385-07

TEMODAR

00085-1244-01
00085-1244-02
00085-1252-01
00085-1259-01
00085-1259-02

TRI NALI N

00085-0703-04

VANCERI L

00085-0736-04
00085-1112-01
00085-1112-03

